Company news
Axsome Therapeutics, Inc. (NASDAQ:AXSM) news
Every Axsome Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
July 15, 2026
Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
July 14, 2026
Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)
July 7, 2026
Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
June 26, 2026
Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month
June 18, 2026
Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026
June 15, 2026
Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting
June 4, 2026
Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation
June 3, 2026
Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month
June 1, 2026
Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP...
May 26, 2026
Axsome Therapeutics Recognizes Mental Health Month
May 7, 2026
Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 4, 2026
Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader
May 1, 2026
Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associate...
April 30, 2026
Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4
April 8, 2026
Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions
April 1, 2026
Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleep...
February 24, 2026
Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 23, 2026
Axsome Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 18, 2026
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.
February 17, 2026
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23
January 27, 2026
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia
January 15, 2026
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue
January 12, 2026
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission
December 31, 2025
Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alz...
December 31, 2025
Axsome Therapeutics to Participate in Upcoming Investor Conferences
November 20, 2025
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
November 6, 2025
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
November 6, 2025
Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
November 3, 2025
Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community
October 9, 2025
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3
October 7, 2025
Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025
September 17, 2025
Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
August 4, 2025
Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline
July 21, 2025
Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4
July 9, 2025
Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21
July 7, 2025
Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month
June 20, 2025
Axsome Therapeutics to Present Data Spanning the SYMBRAVO® (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Mee...
June 18, 2025
Axsome Therapeutics Proudly Supports Migraine and Headache Awareness Month Alongside the Association of Migraine Disorders
June 16, 2025
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025
June 11, 2025
Axsome Therapeutics Announces Availability of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without A...
June 10, 2025
Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia
June 9, 2025
Axsome Therapeutics Presents Data from Three of Its Innovative Neuroscience Programs at the American Society of Clinical Psychopharmacolo...
May 28, 2025
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.
May 27, 2025
Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone
May 13, 2025
Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 5, 2025
Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month
May 1, 2025
Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5
April 8, 2025
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SY...
April 4, 2025
Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MD...
April 1, 2025